摘要
目的探讨益心舒胶囊联合常规西药治疗心房颤动合并舒张性心力衰竭的临床疗效和机制。方法 182例心房颤动合并舒张性心力衰竭患者随机分为治疗组(92例)和对照组(90例),2组患者均给予西药常规治疗,治疗组加用益心舒胶囊4粒.次-1,tid,疗程2 mo。观察2组患者临床症状的有效率,治疗前后心功能指标(心脏超声左室射血分数,左心房内径,舒张期二尖瓣口E峰值、A峰值,E/A等)以及血清BNP、CRP、IL-6和TNF-α等炎症因子的变化。结果治疗组临床症状的有效率、超声左室舒张早期E峰值、E/A均高于对照组(P<0.05),BNP、IL-6以及TNF-α均低于对照组(P<0.01)。结论益心舒胶囊联合西药治疗心房颤动合并舒张性心力衰竭的临床疗效优于单纯西药治疗,其机制可能与其抑制血清IL-6、TNF-α等炎症因子的表达有关。
AIM to investigate the therapeutic effects of Yixinshu capsule on heart function and inflammatory factors in patients with atrial fibrillation and diastolic heart failure. METHODS A total of 182 patients with atrial fibrillation and diastolic heart failure were randomly divided into trial group （92） and control group （90）. The patients in control group were treated with conventional medicine therapy, while the patients in trial group were administered with Yixinshu capsule combined with conventional medicine therapy for 2 months. BNP, CRP, IL-6 and TNF-α were determined. RESULTS There were significant differences of clinical efficacy, peak E velocity, peak A velocity, E/A velocity ratio, BNP, IL-6 and TNF-α between two groups （P 〈 0.05, orP 〈 0.01）. CONCLUSION Yixinshu capsule combined with conventional medicine therapy is effective in patients with atrial fibrillation and diastolic heart failure, which may be associated with the suppression of inflammatory factor, such as IL-6, TNF-α, et al.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2011年第10期766-770,共5页
Chinese Journal of New Drugs and Clinical Remedies
基金
浙江省中医药科研计划资助课题(2007GA003)
